[limarodessa]

Это по-видимому не следует называть "биорезонансом", но новую тему создавать не хотелось бы, а более подходящей не нашел:

[Ссылки доступны только зарегистрированным пользователям ]

Laboratory and clinical evidence suggests that certain frequencies within the RF EMF range of the spectrum may have antitumor effects without causing hyperthermia in patients with breast cancer, HCC, ovarian cancer, thyroid cancer, or glioblastoma multiforme [20]–[22].

[Ссылки доступны только зарегистрированным пользователям ]

The NovoTTF-100A technology applies alternating electric fields by means of electrodes placed on the skin overlying tumor-harboring body parts. This was the first EMF device of its kind approved by the Food and Drug Administration (FDA) of the United States based on the results of a phase III trial for treating recurrent glioblastoma showing efficacy similar to the standard-of-care chemotherapy regimen but with fewer adverse effects[23]

[Ссылки доступны только зарегистрированным пользователям ]

Аbstract
Background:
There is clinical evidence that very low and safe levels of amplitude-modulated electromagnetic fields administered via an intrabuccal spoon-shaped probe may elicit therapeutic responses in patients with cancer. However, there is no known mechanism explaining the anti-proliferative effect of very low intensity electromagnetic fields.

Methods:
To understand the mechanism of this novel approach, hepatocellular carcinoma (HCC) cells were exposed to 27.12 MHz radiofrequency electromagnetic fields using in vitro exposure systems designed to replicate in vivo conditions. Cancer cells were exposed to tumour-specific modulation frequencies, previously identified by biofeedback methods in patients with a diagnosis of cancer. Control modulation frequencies consisted of randomly chosen modulation frequencies within the same 100 Hz–21 kHz range as cancer-specific frequencies.

Results:
The growth of HCC and breast cancer cells was significantly decreased by HCC-specific and breast cancer-specific modulation frequencies, respectively. However, the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. Inhibition of HCC cell proliferation was associated with downregulation of XCL2 and PLP2. Furthermore, HCC-specific modulation frequencies disrupted the mitotic spindle.

Conclusion:
These findings uncover a novel mechanism controlling the growth of cancer cells at specific modulation frequencies without affecting normal tissues, which may have broad implications in oncology.